Skip to content

Trial Summary

This is open-label, multicenter, international study, assessing the efficacy and safety of Trastuzumab deruxtecan (T-DXd) in participants with or without brain metastasis (BMs), with previously-treated advanced/metastatic HER2-positive breast cancer whose disease has progressed on prior anti-HER2-based regimens and who received no more than 2 lines/regimens of therapy in the metastatic setting (excluding tucatinib).



ACTRN/NCT /ethics:


Scientific title:

A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer

Sponsor / Cooperative group:


Trial & Patient Characteristics

Cancer TypeBreast
Trial TypeTreatment
PhasePhase III
Age Range18 Years to 130 Years
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced; Metastatic or Widespread
Anticipated Start Date2021-06-01
Anticipated End Date2024-02-09

Participating Hospitals

HospitalGenesisCare St Andrew's
Clinical Trial CoordinatorKimberley Ruxton
Principal InvestigatorDr Nicholas Murray
Recruitment StatusRecruiting